Association of Newer Glucose‐Lowering Medications and Phenoconversion From REM Sleep Behaviour Disorder to Parkinsonian Disorders in Older Adults with Type 2 Diabetes

It has been estimated that as many as 90% of patients with isolated REM behaviour disorder (iRBD) develop an α-synucleinopathy, yet there are currently no treatments proven to prevent or to delay phenoconversion. This study evaluated the association between glucose-lowering drug classes and incident Parkinson's disease (PD), parkinsonism, and dementia with Lewy bodies (DLB) among older adults with RBD and type 2 diabetes (T2D). We conducted a target trial emulation using a retrospective active-comparator new-user design with 2016-2020 Medicare fee-for-service claims data amongst beneficiaries ≥ 66 years with RBD and T2D and atleast 12 months of continuous enrollment before treatment initiation. We identified initators of glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is) or sodium-glucose cotransporter-2 inhibitors (SGLT-2is). Patients with prior use of either drug during the 12-month baseline period or initiation of both drugs on the index date were excluded. Hazard ratios for incident PD, parkinsonism or DLB were estimated using Cox proportional hazards models with stabilized inverse probability of treatment weighting. Hazard ratios were estimated using Cox proportional regression models with inverse probability of treatment weighting. A total of 148, 144 and 138 patients were included in the GLP-1RA versus DPP-4i, GLP-1RA versus SGLT-2i and SGLT-2i versus DPP-4i cohorts, respectively. Compared with DPP-4i use, GLP-1RA use was associated with a lower risk of PD (HR, 0.02; 95% CI, 0.001-0.20), parkinsonism (HR, 0.08; 95% CI, 0.01-0.96) and the PD or parkinsonism composite (HR, 0.11; 95% CI, 0.01-0.83), but not DLB (HR, 0.45; 95% CI, 0.04-5.37). Similarly, compared with DPP-4i use, SGLT-2i use was associated with a lower risk of PD (HR, 0.03; 95% CI, 0.001-0.97), parkinsonism (HR, 0.02; 95% CI, 0.001-0.87), and their composite (HR, 0.02; 95% CI, 0.001-0.86), but not DLB (HR, 0.94; 95% CI, 0.17-5.17). No statistically significant differences were observed between GLP-1RA and SGLT-2i users. Amongst older adults with RBD and T2D, the risk of incident PD and parkinsonism differed by class of GLDs. Use of GLP-1RAs or SGLT-2is was associated with a lower risk of PD and parkinsonism compared with DPP-4is, while no significant differences were observed for DLB. No statistically significant differences were observed between GLP-1RAs and SGLT-2is. These findings warrant confirmation in studies with longer follow-up and larger sample sizes.

Authors

Institutions

Publication Details

Journal
Journal of Sleep Research
Published
2026-11-18
DOI
https://doi.org/10.1111/jsr.70490
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of Newer Glucose‐Lowering Medications and Phenoconversion From REM Sleep Behaviour Disorder to Parkinsonian Disorders in Older Adults with Type 2 Diabetes

Michael S. Jaffee, Pareeta Kotecha, David E. Vaillancourt, Adolfo Ramirez–Zamora et al.
Journal of Sleep Research
Parkinson's Disease Mechanisms and Treatments
article

Association of Newer Glucose‐Lowering Medications and Phenoconversion From REM Sleep Behaviour Disorder to Parkinsonian Disorders in Older Adults with Type 2 Diabetes

Michael S. Jaffee, Pareeta Kotecha, David E. Vaillancourt, Adolfo Ramirez–Zamora, William Troy Donahoo, Borna Mehrad, Michael F. Presti, Jiang Bian, Majid Lahijani, Michael S. Okun, Jingchuan Guo
article en

Abstract

It has been estimated that as many as 90% of patients with isolated REM behaviour disorder (iRBD) develop an α-synucleinopathy, yet there are currently no treatments proven to prevent or to delay phenoconversion. This study evaluated the association between glucose-lowering drug classes and incident Parkinson's disease (PD), parkinsonism, and dementia with Lewy bodies (DLB) among older adults with RBD and type 2 diabetes (T2D). We conducted a target trial emulation using a retrospective active-comparator new-user design with 2016-2020 Medicare fee-for-service claims data amongst beneficiaries ≥ 66 years with RBD and T2D and atleast 12 months of continuous enrollment before treatment initiation. We identified initators of glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is) or sodium-glucose cotransporter-2 inhibitors (SGLT-2is). Patients with prior use of either drug during the 12-month baseline period or initiation of both drugs on the index date were excluded. Hazard ratios for incident PD, parkinsonism or DLB were estimated using Cox proportional hazards models with stabilized inverse probability of treatment weighting. Hazard ratios were estimated using Cox proportional regression models with inverse probability of treatment weighting. A total of 148, 144 and 138 patients were included in the GLP-1RA versus DPP-4i, GLP-1RA versus SGLT-2i and SGLT-2i versus DPP-4i cohorts, respectively. Compared with DPP-4i use, GLP-1RA use was associated with a lower risk of PD (HR, 0.02; 95% CI, 0.001-0.20), parkinsonism (HR, 0.08; 95% CI, 0.01-0.96) and the PD or parkinsonism composite (HR, 0.11; 95% CI, 0.01-0.83), but not DLB (HR, 0.45; 95% CI, 0.04-5.37). Similarly, compared with DPP-4i use, SGLT-2i use was associated with a lower risk of PD (HR, 0.03; 95% CI, 0.001-0.97), parkinsonism (HR, 0.02; 95% CI, 0.001-0.87), and their composite (HR, 0.02; 95% CI, 0.001-0.86), but not DLB (HR, 0.94; 95% CI, 0.17-5.17). No statistically significant differences were observed between GLP-1RA and SGLT-2i users. Amongst older adults with RBD and T2D, the risk of incident PD and parkinsonism differed by class of GLDs. Use of GLP-1RAs or SGLT-2is was associated with a lower risk of PD and parkinsonism compared with DPP-4is, while no significant differences were observed for DLB. No statistically significant differences were observed between GLP-1RAs and SGLT-2is. These findings warrant confirmation in studies with longer follow-up and larger sample sizes.

Journal of Sleep Research
Regenstrief Institute (US), University of Florida Health (US), University of Florida (US), Indiana University Indianapolis (US), Indiana University School of Medicine (US), Florida College (US)
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon